ALLR
Income statement / Annual
Last year (2023), Allarity Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Allarity Therapeutics, Inc.'s net income was -$11.90 M.
See Allarity Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$120,000.00 |
$1.46 M |
$1.46 M |
$143,277.00 |
$362,287.00 |
$9,974.22 |
| Cost of Revenue |
$37,000.00
|
$120,000.00
|
$106,000.00
|
$86,000.00
|
$0.00
|
$5.08 M
|
$2.22 M
|
$0.00
|
$0.00
|
$55,826.00
|
| Gross Profit |
-$37,000.00
|
-$120,000.00
|
-$106,000.00
|
-$86,000.00
|
$120,000.00
|
-$3.62 M
|
-$761,495.00
|
$143,277.00
|
$362,287.00
|
-$45,851.78
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
1
|
-2.48
|
-0.52
|
1
|
1
|
-4.6
|
| Research and Development Expenses |
$7.87 M
|
$6.93 M
|
$14.20 M
|
$5.13 M
|
$6.37 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$10.03 M
|
$9.96 M
|
$12.36 M
|
$4.10 M
|
$3.87 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.03 M
|
$9.96 M
|
$12.36 M
|
$4.10 M
|
$3.87 M
|
$1.28 M
|
$3.07 M
|
$272,392.00
|
$89,150.00
|
$0.00
|
| Other Expenses |
$0.00
|
$0.00
|
-$474,000.00
|
-$681,000.00
|
$0.00
|
$84,394.00
|
$8,702.80
|
$4.36 M
|
$1.67 M
|
$22,808.00
|
| Operating Expenses |
$17.89 M
|
$16.89 M
|
$26.56 M
|
$9.23 M
|
$10.24 M
|
$1.36 M
|
$3.08 M
|
$4.63 M
|
$1.76 M
|
$22,808.00
|
| Cost And Expenses |
$17.93 M
|
$16.89 M
|
$26.56 M
|
$9.23 M
|
$10.24 M
|
$6.44 M
|
$5.30 M
|
$4.63 M
|
$1.76 M
|
$78,635.00
|
| Interest Income |
$22,000.00
|
$30,000.00
|
$0.00
|
$0.00
|
$7,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$498,000.00
|
$223,000.00
|
$499,000.00
|
$227,000.00
|
$3.31 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$37,000.00
|
$120,000.00
|
$106,000.00
|
$86,000.00
|
$85,000.00
|
$32,530.00
|
$8,702.80
|
$278,211.00
|
$265,217.00
|
$22,808.00
|
| EBITDA |
-$12.08 M |
-$17.24 M |
-$25.91 M |
-$6.01 M |
-$15.58 M |
-$4.90 M |
-$3.83 M |
-$4.21 M |
-$1.13 M |
-$45,852.30 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
-83.83
|
-3.35
|
-2.63
|
-29.38
|
-3.12
|
-4.6
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
-146.76
|
-3.41
|
-2.63
|
-31.32
|
-3.85
|
-6.88
|
| Total Other Income/Expenses Net |
$5.31 M
|
-$687,000.00
|
$41,000.00
|
$1.90 M
|
-$8.86 M
|
$1.53 M
|
-$1.15 M
|
$37,987.00
|
-$130,577.85
|
$0.00
|
| Income Before Tax |
-$12.62 M
|
-$17.58 M
|
-$26.52 M
|
-$7.23 M
|
-$18.98 M
|
-$3.46 M
|
-$4.99 M
|
-$4.45 M
|
-$1.53 M
|
-$68,661.18
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-158.14
|
-2.37
|
-3.42
|
-31.06
|
-4.22
|
-6.88
|
| Income Tax Expense |
-$717,000.00
|
-$1.52 M
|
$133,000.00
|
-$2.16 M
|
-$4.58 M
|
$1.07 M
|
$95,086.00
|
$766,892.00
|
$380,158.00
|
$0.00
|
| Net Income |
-$11.90 M
|
-$16.06 M
|
-$26.65 M
|
-$5.07 M
|
-$14.40 M
|
-$2.29 M
|
-$4.90 M
|
-$3.68 M
|
-$1.15 M
|
-$68,661.18
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-120
|
-1.57
|
-3.36
|
-25.7
|
-3.17
|
-6.88
|
| EPS |
-0.0103 |
-1856055 |
-3520104 |
-1698639 |
-189613 |
0 |
0 |
0 |
0 |
-0.0587 |
| EPS Diluted |
-0.0103 |
-1856055 |
-3520104 |
-1698639 |
-189613 |
0 |
0 |
0 |
0 |
-0.0587 |
| Weighted Average Shares Out |
$1.99 B
|
$11.34
|
$7.57
|
$3.89
|
$3.89
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.17 M
|
| Weighted Average Shares Out Diluted |
$1.99 B
|
$11.34
|
$7.57
|
$3.89
|
$3.89
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.17 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
